Altimmune Stock News

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 20

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

One privacy-focused altcoin is surging by more than 40% this week, defying an up-and-down digital asset market.

A popular cryptocurrency analyst is bullish on Ethereum (ETH) and singles out one altcoin that might outperform other large-cap crypto assets.

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

If the preliminary evidence is borne out, they just might be.

Neo initially tried to rally on Wednesday but gave back gains rather quickly as we have fallen back towards the $20 level.

The FDA has cleared Altimmune Inc''s (NASDAQ: ALT ) Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity. Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist under development to treat obesity and nonalcoholic steatohepatitis (NASH). Altimmune expects to initiate the Phase 2 trial in obesity in Q1 of 2022. The Phase 2 clinical trial will enroll approximately Full story available on Benzinga.com

The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity.  [ALERT] Nic Chahine shares his Bear Market Beating options tra

Altimmune Inc (ALT) shares closed today at 0.9% above its 52 week low of $8.10, giving the company a market cap of $329M. The stock is currently down 9.6% year-to-date, down 41.4% over the past 12 months, and up 109.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 48.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Industrials industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -697.0% The company's stock price performance over the past 12 months lags the peer average by 6448.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimm

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmun

Altimmune is changing its focus from infectious diseases towards metabolic and liver diseases. The company is leaning on Pemvidutide for obesity, NAFLD, and NASH. So far, the dual GLP-1/glucagon recep